Glucagon is released from the endocrine pancreas in response to a meal and binds to G protein-coupled receptors on skeletal muscle and the liver to exert its glucoregulatory effects
Moreover, studies have reported no significant side effects, adding to their appeal
RD Lawrence Lecture 2008: Targeting GLP-1 release as a potential strategy for the therapy of Type 2 diabetes
In the context of GLP-1s, microdosing offers a promising strategy for individuals who may benefit from the metabolic and anti-inflammatory effects of these drugs without needing high doses typically prescribed for diabetes or obesity
That said, fiber-rich foods (legumes, oats, onions, Jerusalem artichoke), higher-protein meals, and fermented foods can each modestly support your body's own GLP-1 and satiety signaling through the microbiome and L-cell pathways described above
The Dosage Clinical trials used various doses, with the 12 mg dose providing the biggest impact